Guest Profile

Dr. Roger Stupp

Dr. Roger Stupp trained in Internal Medicine in Switzerland and in Hematology/Oncology at the University of Chicago. He then worked over 17 years as a physician and researcher at the University of Lausanne, and from 2013 - 2017 as the Director of the Department of Oncology at the University Hospital in Zurich, Switzerland. Since April 2017 he holds an appointment as Division Chief of Neuro-Oncology and Co-Director of the Brain Tumor Institute and Associate Director for Strategic Initiatives of the Robert H. Lurie Comprehensive Cancer Center. Dr. Stupp has been a member of the European Organisation for Research and Treatment of Cancer (EORTC) since 1994, and serves as a member of the Board of Directors and Executive Committee since 2006, as their President from 2012 - 2017.

Dr. Stupp's research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. Roger Stupp is best known for his contributions in landmarks trials establishing temozolomide and, most recently tumor treating fields as the standard of care for glioblastoma patients. In 2017 he took new responsibilities as leader of medical neuro-oncology and cancer research within Northwestern Universities Robert H. Lurie Comprehensive Cancer Center and the Brain Tumor Institute. He remains dedicated to translational cancer research, scientific cooperation and believes in the importance of well-designed clinical trials conducted within academic cooperative groups.